Results 81 to 90 of about 2,325 (161)

Targeting glutamine synthetase with AS1411-modified exosome-liposome hybrid nanoparticles for inhibition of choroidal neovascularization

Journal of Nanobiotechnology
Choroidal neovascularization (CNV) is a leading cause of visual impairment in wet age-related macular degeneration (wAMD). Recent investigations have validated the potential of reducing glutamine synthetase (GS) to inhibit neovascularization formation ...
Miaomiao Zhang, Xinyue Lu, Lifu Luo, Jinqiu Dou, Jingbo Zhang, Ge Li, Li Zhao, Fengying Sun   +7 more
doaj   +1 more source

Anti-Nucleolin Aptamer AS1411 [PDF]

, 2020
openaire   +1 more source

As1411-modified liposomes to enhance drug utilization and augment the anti-tumor efficacy

Cancer Nanotechnology
Background The utilization of liposomes in drug delivery has garnered significant attention due to their efficient drug loading capacity and excellent biocompatibility, rendering them a promising platform for tumor therapy.
Danhuan Zhang, Lingyun Chen, Yang Zhao, Hao Ni, Qiuying Quan, Jun Ma, Lingchuan Guo   +6 more
doaj   +1 more source

Preparation of Bmi-1-siRNA Lipid Nanoparticles and Effects in Gastric Cancer

Nano Biomedicine and Engineering
Malignant tumors remain a serious threat to human health and life and are a major public health problem globally. Herein, we designed and synthesized a novel nucleic acid nanomedicine AS1411-siRNA-LNPs (As@LNPs).
Hongzhang Yan, Hong Shen, Jinrong SiTu, Yingying Yang, Lingle Zhang, Kai Yang   +5 more
doaj   +1 more source

Enhancement of Radiosensitization by Silver Nanoparticles Functionalized with Polyethylene Glycol and Aptamer As1411 for Glioma Irradiation Therapy. [PDF]

Int J Nanomedicine, 2019
Zhao J, Liu P, Ma J, Li D, Yang H, Chen W, Jiang Y.   +6 more
europepmc   +1 more source

Multifunctional molecular hybrid for targeted colorectal cancer cells: Integrating doxorubicin, AS1411 aptamer, and T9/U4 ASO.

PLoS ONE
Colorectal cancer (CRC) poses a global health challenge, with current treatments often harming both cancerous and normal cells. To improve efficacy, a multifunctional drug delivery platform has been developed, integrating bioactive materials, anticancer ...
Kanpitcha Jiramitmongkon, Pichayanoot Rotkrua, Paisan Khanchaitit, Jiraporn Arunpanichlert, Boonchoy Soontornworajit   +4 more
doaj   +1 more source

Robust aptamer–polydopamine-functionalized M-PLGA–TPGS nanoparticles for targeted delivery of docetaxel and enhanced cervical cancer therapy

International Journal of Nanomedicine, 2016
Guojun Xu,1–3,* Xinghua Yu,2,* Jinxie Zhang,1,2,* Yingchao Sheng,4 Gan Liu,2 Wei Tao,1,2 Lin Mei1,2 1School of Life Sciences, Tsinghua University, Beijing, 2Graduate School at Shenzhen, Tsinghua University, Shenzhen, 3School of Materials Science ...
Xu GJ, Yu XH, Zhang JX, Sheng YC, Liu G, Tao W, Mei L   +6 more
doaj  

Correction: Aptamer AS1411 interacts with the KRAS promoter/hnRNP A1 complex and shows increased potency against drug-resistant lung cancer. [PDF]

RSC Med Chem
Zhu Y, Li X, Zhang Q, Yang X, Sun X, Pan Y, Yuan X, Ma Y, Xu B, Yang Z.   +9 more
europepmc   +1 more source

Selective alkylation and bioactivity of phosphorothioated nucleolin aptamer AS1411

Journal Of Chinese Pharmaceutical Sciences, 2017
openaire   +1 more source

Aptamers in cancer therapy: Why has clinical translation lagged behind preclinical promise? [PDF]

Biomed Pharmacother
Tran TT, Tran VL, Fishel ML, Nguyen BT, Zhang J, Condello S, Zhong X, Schmidt M.   +7 more
europepmc   +1 more source